Thiopurines are widely used immunosuppressive agents. In high dosages, they inhibit the purine synthesis and are considered to be possibly harmful to spermatogenesis, and subsequently to men's fertility and their offspring. However, the clear association between thiopurine exposure and male fertility and reproduction safety, if any, is still poorly understood.
OBJECTIVE AND RATIONALE:
The aim of this review was to systematically summarize and meta-analyse the available data, derived from animal and human studies, regarding the influence of thiopurine exposure on fertility and conception safety in men and their offspring.
Introduction
Thiopurines, available as the derivatives azathioprine, mercaptopurine and thioguanine, are widely used antimetabolite and immunosuppressive drugs. They were introduced in the early 1950s, initially as a chemotherapy for the treatment of haematological malignancies (i.e. paediatric acute lymphoblastic leukaemia, adult acute lymphoblastic leukaemia, paediatric acute myeloid leukaemia and paediatric non-Hodgkin lymphoma) (Elion, 1989; Sahasranaman et al., 2008) . The prefix 'thio' in thiopurine is derived from the original mechanism of action in these agents, which is the substitution of oxygen by sulphur at the 6′-position of purine bases, and consequently the inhibition of the cell cycle of leukaemic cells (Elion et al., 1953) . When thiopurines are administered in lower dosages (thioguanine 0.2-0.3 mg/kg, azathioprine 2.0-2.5 mg/kg and mercaptopurine 1.0-1.5 mg/kg), they induce anti-inflammatory effects and immunomodulation by inducing T-lymphocyte apoptosis ( Fig. 1 ) (Quemeneur et al., 2003; Van Asseldonk et al., 2009; Duley and Florin, 2005) . Hence, over the past 65 years thiopurines have been adapted in the treatment of several chronic inflammatory and autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus (SLE), psoriasis, eczematous and immunobullous diseases, myasthenia gravis, multiple sclerosis, inflammatory bowel disease (IBD) and autoimmune hepatitis, and have been used to prevent organ transplant rejection (Karran and Attard, 2008; Derijks et al., 2006; Zweiman, 1973; Silvis and Levine, 1999; Hubener et al., 2016; Gold et al., 2008; Stankiewicz et al., 2013) . Azathioprine, mercaptopurine and thioguanine are all on the World Health Organization's (WHO) Essential Medicines List (EML), a global concept which presents the most effective, safe and cost-effective drugs to meet priority health needs (Laing et al., 2003) . Especially in IBD, a condition which affects both men and women equally, thiopurines play an important role in the maintenance treatment of both Crohn's disease and ulcerative colitis (Mowat et al., 2011) . It is estimated that over 1 million people in the United States and 2.5 million people in Europe suffer from IBD, and approximately one-third of them uses one or more thiopurine-derivatives during the course of disease (Kaplan, 2015; van den Heuvel et al., 2016) . In the dermatology, the thiopurine-derivative azathioprine has been utilized for decades as a steroid-sparing agent, and is a first-line medication in treating generalized eczematous disorders, photodermatoses and pemphigoid (Schram et al., 2011; Patel et al., 2006) . In more detail, based on the findings from the Newport Database on use of generics (date: 31 March 2017), the annual worldwide consumption of azathioprine has been estimated at approximately 41 000 kg (between 600 000 and 800 000 patients) and that of mercaptopurine at approximately 2 800 kg (between 70 000 and 100 000 patients) (Newport Premium™ (for Generics) by Thomson Reuters). Thioguanine is used in the management of haematological malignancies and as an escape therapy in patients who are intolerant or unresponsive to azathioprine or mercaptopurine, especially in IBD (currently, about 3000 IBD patients are using this drug in The Netherlands) (Simsek et al., 2017) .
In view of the fact that thiopurines may interfere with nucleic acid synthesis, it effects on rapidly dividing somatic and germ cells, such as spermatozoa, raises questions regarding their usage in patients wishing to conceive (Fig. 2) (Polifka and Friedman, 2002; Mosesso and Palitti, 1993; Brown et al., 2017) . Mechanisms such as thiopurine-induced sperm cell apoptosis (cytotoxic action), germ cell mutations (genotoxic or mutagenic action), inheritance of these mutations or transmission of thiopurine metabolites to the female and foetus trough seminal plasma (teratogenic action) or by interfering with the secretion of gonadal or pituitary hormones (gonadotoxic action), have been proposed as ways in which these drugs could adversely affect fertility and reproduction in men (Klemmt and Scialli, 2005; Mosesso and Palitti, 1993; Voogd, 1989) . The Food and Drug Administration (FDA) classified thiopurines as category D, indicating that they may have potential risks of adverse events to the foetus. In animal studies, azathioprine and mercaptopurine caused chromosomal damage and aberrations in germ cells of various rodents (already in doses of two times the human equivalent dose (HED)) (Polifka and Friedman, 2002) . Azathioprine and mercaptopurine in lower dosages, as used in the treatment of immune-mediated disorders, were not teratogenic, however poorer pregnancy outcomes in exposed mice did indicate occult sperm damage (Ligumsky et al., 2005) . In humans, fewer studies have evaluated the association between thiopurines and fertility and reproduction safety. Most trials in this field have focused on maternal thiopurine exposure in which these agents are considered safe prior to and during pregnancy when administered in low but adequate dosages (Kanis et al., 2017; Akbari et al., 2013; Francella et al., 2003; Hutson et al., 2013) . Relatively less is known concerning fertility and conception safety in thiopurine exposed male patients, and the available literature is conflicting (Polifka and Friedman, 2002; Millsop et al., 2013; Brown et al., 2017; Semet et al., 2017) . Questions about the potential of thiopurines to induce chromosomal damage in male germ cells, or to adversely affect testicular function, semen quality and birth outcomes, remain to be answered.
The possible reproductive toxicity of several other cytostatic drugs, used for immunosuppression in non-malignant diseases in men, have been a topic of discussion as well (Brogan and Dillon, 2000; Gutierrez and Hwang, 2017; Semet et al., 2017) . Methotrexate is evidently teratogenic in women and probably causes reversible oligospermia, but seems to have minimal risks to the foetus when the male partner is treated (Gutierrez and Hwang, 2017) . Cyclosporine, a calcineurin inhibitor, adversely affected semen quality and testicular function in rodents and in male renal transplantation (Tx) recipients, but this was transient and fertility recovered completely after 2 years from the transplatatopn (Georgiou et al., 2016) . Cyclophosphamide, used to treat malignancies and kidney diseases, is teratogenic in the first trimester and has a deleterious effect on testicular functions (Ozolins, 2010) . Chlorambucil was highly mutagenic in male germ cells of diverse animals (Barnett and Lewis, 2003) . In preadolescent children with nephrotic syndrome, dosages under 10 mg/kg did not Figure 1 Simplified thiopurine metabolic pathway when inducing anti-inflammatory effects and immunomodulation (using relatively low dosages).
Azathioprine (AZA) is converted, by separating the imidazole group, to mercaptopurine (MP), which is converted into the pharmacologically active 6-thioguanine nucleotides (6-TGNs) through a multistep-pathway needing hypoxanthine-guanine phosphoribosyl transferase (HGPRT), inosine monophosphate dehydrogenase (IMPDH) and guanosine monophosphate synthetase (GMPS). The 6-TGNs consist of 6-thioguanine monophosphate (6-TGMP), 6-thioguanine diphosphate (6-TGDP) and 6-thioguanine triphosphate (6-TGTP). The 6-TGTP nucleotides target Ras-related C3 botulinum toxin substrate 1 (Rac1) and induce T-cell apoptosis. Thioguanine (TG) is converted into 6-TGNs in one step needing HGPRT. Through thiopurine S-methyltransferase (TPMT), 6-methylmercaptopurine (6-MMP) and 6-methylmercaptopurine ribonucleotides (6-MMPR) are generated. Figure 2 Simplified thiopurine metabolic pathway when inducing inhibition of DNA synthesis (using relatively high dosages). A visual representation of the existing literature on the effects of thiopurines in leucocytes and sperm cells. In leucocytes, azathioprine (AZA), mercaptopurine (MP) and thioguanine (TG) are converted into pharmacologically active 6-thioguanine nucleotides (6-TGNs). These 6-TGNs are built into DNA as fraudulent bases and consequently induce cell death. It is unclear whether thiopurines affect other rapidly dividing cells, such as sperm cells. affect semen quality, but dosages above 18 mg/kg caused azoospermia (Callis et al., 1980) . Furthermore, it has been debated whether corticosteroid use affects fertility or reproduction outcome in men (Sands et al., 2015; Larsen et al., 2017) . In animal studies, prednisone induced dose-related teratogenic and toxic effects, with increased rates of cleft palate, foetal loss and foetal growth restriction (Reinisch et al., 1978) . Exogenous corticosteroid exposure in men could inhibit the hypothalamic-pituitary-gonadal axis and subsequently affect spermatogenesis, however, low dose corticosteroid therapy, as used to treat flares in inflammatory diseases, did not significantly affect male fertility or increase the risk of congenital abnormalities (Larsen et al., 2017; Semet et al., 2017; Whirledge and Cidlowski, 2010; Sands et al., 2015) . In addition, prednisone treatment (in dosages of 5 mg/day) improved seminal quality in men with genital inflammations or antisperm antibodies (Omu et al., 1996; Milardi et al., 2017) . It is essential to underline that patients treated with these immunosuppressive drugs, including thiopurines, have serious illnesses and sexual and reproductive health might be disturbed by both disease and therapy-related factors (Ostensen, 2017) .
Chronic inflammatory and autoimmune diseases, such as SLE and IBD, which are managed with thiopurines, predominantly affect young adults (Kuek et al., 2007) . Additionally, solid organ transplantation is essential in children and (pre)adolescents with (end-stage) organ failure (Lipshultz et al., 2014) . Appropriate counselling regarding fertility, conception, and the possible toxic effects of paternal thiopurine use, is essential in the management of the underlying disease in potential fathers. The aim of this review was to systematically summarize and meta-analyse the available data, derived from animal and human studies, regarding the influence of thiopurine exposure on fertility and reproduction safety in men.
Methods

Search strategy
This study was performed according the checklist provided in the 'Preferred Reporting Items for Systematic Reviews and Meta-Analyses' (PRISMA) statement for writing systematic reviews and meta-analyses (Moher et al., 2009 ). This study was not registered in PROSPERO, because data extraction was almost completed when registration was attempted (Chien et al., 2012) . A systematic literature search of the MEDLINE database, using PubMed, and the EMBASE database was performed applying the following MeSH/Emtree and text terms with asterisks (*) where applicable: 'azathioprine, mercaptopurine, thioguanine, tioguanine, thiopurine, fertility, infertility, semen, sperm, testis, testes, paternal exposure, reproduction, conception, pregnancy, birth, congenital, foetus, teratogen and mutagen' (Supplementary Fig. 1 ). The whole search was combined with the terms 'male, man, men, father and paternal' to identify specific studies focused on fertility in men. The search was not exclusively restricted to human subjects or to a type of disease or condition, to gather and summarize all available studies with regards to this topic. All published articles on thiopurines and male fertility, written in English and published until May 2017, were screened for eligibility. References from selected articles were cross-checked to identify applicable studies to include in this systematic review. Additionally, the Clinical Trials Registry of the United States National Institutes of Health (NIH) was searched for applicable studies, but studies on thiopurines and fertility or conception were not found.
Study selection
All studies were screened on title and abstract by the first and last author (MS and NdB) to determine eligibility. Studies were included if they reported outcomes on fertility (i.e. sexual and testicular function, semen quality and germ cell mutagenicity) or paternal drug exposure (i.e. mutagenicity, teratogenicity, pregnancy and birth outcomes) in thiopurine exposed men. Studies which did not differentiate between thiopurines and other concomitant cytostatic/immunosuppressive treatment (e.g. sulfasalazine, tacrolimus, busulfan, chlorambucil, mycophenolate mofetil, cyclophosphamide, cyclosporine, methotrexate) or X-ray therapy, were excluded with an exception of prednisone therapy. Corticosteroids are important in treating flares in inflammatory and autoimmune diseases and despite the relatively low level of evidence, prednisone therapy has not shown to adversely affect spermatogenesis or paternally exposed offspring (Semet et al., 2017; Larsen et al., 2017) . Furthermore, studies without original data on fertility and reproduction in thiopurine exposed men were excluded. Disagreements regarding study eligibility were resolved by discussion between the first and last author (MS and NdB). In cases of indecisiveness, the second author (CBL, Professor of Gynaecology and Obstetrics) made the decision.
Data extraction and quality assessment
If records were eligible, data were systematically collected and imported into an electronic database by the first and last author (MS and NdB) . This included the following data: study design, thiopurine classification, dosage, duration, route of administration, disease characteristics, number of exposed and unexposed patients, study outcome, results and conclusion of the authors. Furthermore, the GRADE guidelines were used to assess the quality of evidence (including risk of bias) of the original studies performed in humans, and were rated as very low, low, moderate or high (Balshem et al., 2011) .
Data synthesis and analysis
Case reports and case series were described structurally. Case-control studies or cohorts with control groups were included in the metaanalysis. These were all studies which reported on birth outcomes in paternally thiopurine exposed and unexposed offspring. Birth outcomes were reported as odds ratios (ORs) which represented the odds of congenital defects in paternally exposed offspring compared to the control groups. Pooled ORs, with associated 95% confidence intervals (CI), were calculated using the random effects model to account for possible heterogeneity between the studies. Heterogeneity was assessed by the χ 2 and I 2 -tests: the χ 2 test was used to assess the presence of heterogeneity and the I 2 test was used to determine the percentage of heterogeneity due to variation between studies. Initially, funnel plots would be used to assess the potential for reporting bias (including publication bias), however due to the small number of study inclusions in this meta-analysis, this was not performed. Probability (P)-values under 0.05 were considered statistically significant. All statistical analyses were performed using the software Microsoft R Version 3.2.5 (Redmond, Washington, USA).
Results
Description of included studies
The search strategy in the MEDLINE and EMBASE databases yielded 277 and 327 articles, respectively, which were screened for eligibility (Fig. 3) . After removing the duplicates, 413 articles were screened on title and abstract. Of these, 315 articles were excluded, mainly due to lack of (original) data on thiopurines, or because the association of thiopurines with fertility in women and/or maternal exposure, was described. Additionally 71 articles were excluded due to a lack of original research data (n = 23), lack of data on male fertility (n = 28), concomitant use of cytotoxic agents or X-ray (n = 13) and language restrictions (n = 7). One additional, often discussed, case report (Ben-Neriah and Ackerman, 2001) outside of the original search was included. In total, 28 articles were included in this review. Fourteen animal trials studied the germ cell mutagenicity and/or teratogenicity of azathioprine and mercaptopurine in mice (n = 10), rats (n = 3) and fruit flies and fungus (n = 1). In the majority of these studies, thiopurines were injected subcutaneously, intraperitoneally or intravenously and administered in exceeding dosages as used in humans. The drug characteristics (dosage, duration and route of administration) and the study results are summarized in Table I . To calculate the equivalent drug doses used in animal species to HEDs, a formula based on body surface area (of mice, rats and humans) was applied (Table I) (Reagan-Shaw et al., 2008) .
Fourteen studies performed in humans (six studies in IBD patients, four studies in renal Tx recipients, one study in SLE patients, and three studies where the underlying disorders was not mentioned), were included in this systematic review. Six studies, mainly case series, reported outcomes on semen quality in thiopurine exposed men. Eight studies, including six case-control trials, reported data on birth defects in paternally thiopurine exposed offspring. These six case-control studies were included in the meta-analysis. Furthermore, seven out of the fourteen human studies described the effect of azathioprine exposure, two studies mercaptopurine exposure and five studies did not distinguish between azathioprine and mercaptopurine. No studies on the effects of thioguanine exposure on male fertility were identified. A detailed list of the study and patients characteristics is given in Table II .
Animal models
Mercaptopurine
The toxicity and germ cell mutagenicity of mercaptopurine have been studied in several animal studies (n = 11). Mercaptopurine-induced mutagenicity in germ cells of male mice and rats in the early spermatocyte stages, without affecting the late meiotic and post-meiotic cell stages (Generoso et al., 1975; Sykora, 1981; Moreland et al., 1981) . Spermatocytes, as compared to spermatogonia and spermatids, were most sensitive to mercaptopurine exposure as observed in in vitro studies (Habas et al., 2016 (Habas et al., , 2017 . Additionally, chromosomal Low dosed MP, as used in IBD therapy, did not adversely affect spermatogenesis or testicular function (testicular weight and plasma testosterone) in exposed mice.
None
Continued damage in rat spermatocytes was already observed in mercaptopurine dosages starting from 0.05 mM, compared to mouse spermatocytes, in which doses starting from 0.5 mM were spermatotoxic, indicating a major difference in sensitivity between these two species (Habas et al., 2016 (Habas et al., , 2017 . The rate of mercaptopurine-induced mutagenicity and lethality seemed to be dose dependent in multiple studies (Generoso et al., 1975; Moreland et al., 1981; Sheu and Moreland, 1983) . Mercaptopurine was not toxic at 12.5 mg/kg, but lethal and mutagenic at 50 mg/kg both in male mice and rats (Moreland et al., 1981; Sheu and Moreland, 1983) . When male mice were exposed to different dosages of mercaptopurine (4.3, 10, 15, 25, 50 or 200 mg/kg), the rate of mutagenicity was the highest in mice exposed to intraperitoneal mercaptopurine for 14 days (Sykora, 1981) . In multiple studies, it was observed that a single dose of intraperitoneally administered mercaptopurine (in 150 or 300 mg/kg) did not induce altered spermatogenesis or reduce fertility, or cause an increased mutagenicity in paternally exposed offspring (Meistrich et al., 1982; Oakberg et al., 1982; Russell and Hunsicker, 1987) . However, several types of abnormalities in the sperm were observed, such as the production of diploids and abnormally shaped sperm cells (Meistrich et al., 1982) .
In two animal studies, mercaptopurine was administered in relatively low dosages as used in the treatment of immune-mediated diseases such as IBD. Male mice (n = 37), daily exposed to 2, 5 or 8 mg/kg of mercaptopurine for 51 days, did not have an impaired sperm quality or an increased rate of birth defects in their offspring (Ligumsky et al., 2005) . However, a significant poorer pregnancy outcome in all exposed mice, as compared to unexposed mice, indicated occult sperm damage (pregnancy rate in exposed group: 41%, 28% and 16% for 2, 5 and 8 mg/kg, respectively, as compared to 55% pregnancy rate in the control group, P < 0.001 for the 2 and 5 mg/kg groups and P < 0.01 for the 8 mg/kg group). In male rats, testicular function (testicular weights, serum testosterone levels, human chorionic gonadotropin (HCG) levels) and rate of spermatogenesis were comparable between two treatment groups (group 1:3 mg/kg and group 2:5 mg/kg, daily for 75 or 24 days), and between mercaptopurine exposed rats and unexposed controls (testicular weight in gram: 3.7 ± 0.1 in Group 1, 4.0 ± 0.2 in Group 2, 3.4 ± 0.1 in controls, number of spermatids per gram/testis: 120 × 10 6 in Group 1, 122 × 10 6 in Group 2 and 118 × 10 6 in controls, all P > 0.05) (Karl et al., 1991) . The researchers concluded that the harmful effects of mercaptopurine were dose dependent, and testicular function and fertility remained unaffected in low dosages.
Azathioprine
The germ cell toxicity of azathioprine has been studied in three animal trials (Bendre et al., 2005 (Bendre et al., , 2007 Clark, 1975) . Azathioprine administered in 50 and 100 mg/kg for 4 weeks induced impaired sperm viability, and a dose of 25 mg/kg for 16 weeks reduced the sperm motility in male mice (Bendre et al., 2005) . Azathioprine was not genotoxic at lower doses (< 10 mg/kg), but a reduction in testicular weight was even seen in animals treated with a low dose of 5 mg/kg. In male mice exposed to 5 or 10 mg/kg azathioprine for a longer period (24 weeks), the risk of germ-line mutations was not increased (Bendre et al., 2007) . In another study, azathioprine was administered orally in acute (50 mg/kg over two days) or chronic (50 mg/kg/week for 10 weeks) dosages to male mice, 5 mg SLE, systemic lupus erythematosus; AZA, azathioprine; Tx, transplantation; P, prospective; R, retrospective; IBD, inflammatory bowel disease; MP, mercaptopurine; WAGR, Wilms tumour, aniridia, genital anomalies and retardation; N.A., not available. a Rating of the quality of evidence of the studies based on the GRADE guidelines (Balshem et al., 2011) . b Effect of thiopurines on fertility and reproduction in exposed men, as concluded by the researchers of the original studies.
azathioprine was orally fed to fruit flies (Drosophila melanogaster) and 120 mg azathioprine was administered to fungus (Neurospora crassa) (Clark, 1975) . The researchers observed that azathioprine induced germ cell mutations in all three species and caused, especially in longterm administered dosages, transiently impaired semen quality (sperm viability in particular) in male mice.
Transplantation medicine
Male fertility
In an open-label trial, the spermatogenesis of eleven renal Tx recipients on azathioprine (1-2 mg/kg daily) and prednisone co-therapy was studied and compared with eight patients on haemodialysis treatment (ages ranged from 18 to 45 years) (Phadke et al., 1970) . The patients had to answer a questionnaire on their sexual activity and the majority underwent a testicular biopsy (in 11 renal Tx recipients and 5 haemodialysis patients) and semen analysis (in 8 renal Tx recipients and 5 haemodialysis patients). Renal Tx recipients had improved spermatogenesis with adequate cellularity and normal sexual desire and performance, as compared to the haemodialysis patients, probably as an adequate treatment of the renal failure. Furthermore, renal Tx recipient had sperm of good quality including normal sperm counts, sperm motility and morphology. In a comparable study, there were no significant differences in testicular function between fifteen renal Tx recipients treated with azathioprine (ranging from 1 to 3 mg/kg daily) and healthy controls (n = 158) (testicular volume 22.0 ± 1.6 ml vs. 24.9 ± 0.4 ml, plasma luteinizing hormone (LH) 6.0 ± 0.6 vs. 5.5 ± 0.2 IU/I, plasma follicle-stimulating hormone (FSH) 8.9 ± 1.0 vs. 5.5 ± 0.2 IU/I, plasma testosterone 17.4 ± 1.3 vs. 23.8 ± 0.6 nM/l, plasma prolactin 10.3 ± 1.4 vs. 5.9 ± 0.3 ng/ml, all P > 0.05) (Handelsman et al., 1984) . In a case series, a subnormal sperm quality was observed in almost all thiopurine treated renal Tx recipients (ages ranged from 23 to 57 years) with normal renal functions, but a correlation between azathioprine administration and spermatic defects was not present (Lingardh et al., 1974) .
Birth outcomes
The possible mutagenicity of azathioprine in paternally exposed offspring was reported in one small cohort-study in which ten infants of eight renal Tx recipients underwent a cytogenetic analysis (McGeown and Nevin, 1978) . Nine of ten infants had a normal cytogenetic profile, one child had a trisomy 21 syndrome. Chromosome examination showed a mean chromosome damage of 1.4% in the healthy infants and 8% damage in the patient with Down's syndrome. A relationship between the syndrome and thiopurine exposure was unclear.
Inflammatory bowel disease
Male fertility
In a prospective study, the sperm quality (sperm density, motility, morphology, ejaculate volume and total sperm count) of eighteen IBD patients (ages ranged from 18 to 57 years) treated with 1.5-2 mg/kg azathioprine daily for at least 3 months, was examined and compared to the standards proposed by the WHO (Dejaco et al., 2001) . Smoking and alcohol status and disease activity were taken in the analysis. In all patients, the semen parameters were within the normal ranges (total sperm count 297 ± 272 Mio (94% within WHO standard), sperm density 94 ± 84 Mio/mL (94% within WHO standard), motility 60% ± 20% (67% within WHO standard), normal morphology 44% ± 21% (67% within WHO standard) and ejaculate volume 3.4 ± 1.5 mL (89% within WHO standard)). In ten patients, a semen analysis was performed before and during azathioprine therapy, without any significant differences in semen parameters (total sperm count 247 ± 184 vs. 376 ± 341 Mio, sperm density 106 ± 75 vs. 107 ± 105 Mio/mL, motility 59% ± 19% vs. 61% ± 24%, normal morphology 45% ± 24% vs. 41% ± 22% and ejaculate volume 3.0 ± 1.7 vs. 3.7 ± 1.6 mL, all P ≥ 0.1). In addition, semen analyses were performed in five patients during long-term treatment (49 ± 14 months), showing normal semen parameters in all of them (total sperm count 163 ± 91 vs. 342 ± 189 Mio, semen density 49 ± 23 vs. 107 ± 41 Mio/mL, motility 52% ± 18% vs. 64% ± 20%, normal morphology 24% ± 12% vs. 48% ± 18% and ejaculate volume 3.4 ± 1.2 vs. 3.2 ± 0.9 mL, all P ≥ 0.1). There was no control group in this study, but the researchers did a follow-up and observed seven healthy infants which were fathered by six of the included patients.
In a recent cross-sectional study, thirteen men with Crohn's disease and five men with ulcerative colitis on azathioprine or mercaptopurine therapy did not have a significant different seminal quality (including sperm quality, antisperm antibodies, zinc-level) and testicular function compared to healthy controls (n = 22) (median sperm count 35.5 (interquartile range: 19.7-69) vs. 51 (24-100) million/ml, motility 46 ± 21.3 vs. 43.8 ± 22.2, vitality 68.1 ± 13.8 vs. 63 ± 21.2 and morphology 9.6 ± 7.2 vs. 9.6 ± 5 million/ml, all P > 0.05) (Valer et al., 2017) . The researchers observed that seminal quality tended to be poorer (lower seminal zinc levels, sperm count and motility) in men with Crohn's disease, as compared to men with ulcerative colitis, without an association with IBD disease activity, antisperm antibodies and zinc deficiency.
Birth outcomes
The possible teratogenic risks of paternally thiopurine exposure to the foetus was studied in three retrospective studies (Rajapakse et al., 2000; Francella et al., 2003; Teruel et al., 2010) . Rajapakse et al. studied pregnancy and birth outcomes by men who conceived during mercaptopurine use (Group 1A, n = 13) and those who conceived at least 3 months after mercaptopurine was discontinued (Group 1B, n = 37) (Rajapakse et al., 2000) . These groups were compared with pregnancies fathered by men with IBD without any mercaptopurine use (Group 2, n = 90). There were two cases of congenital abnormalities and two spontaneous abortions in Group 1A, one spontaneous abortion in Group 1B and two spontaneous abortions in Group 2. The incidence of pregnancy-related complications was significantly increased when the fathers were exposed to mercaptopurine during conception, as compared to the other groups (Group 1A compared to Group 1B: OR 16, 95% CI 1.6, 161, P < 0.05 and Group 1 A compared to Group 2: OR 19.6, 95% CI 3.1, 122, P < 0.05). With regard to the children, there were no differences in terms of birth weight, childhood illnesses, or growth and development.
In a comparable study, the pregnancy and birth outcomes for fathers with IBD (ages ranging from 18 to 51), who were treated with mercaptopurine before (n = 44 pregnancies, range after mercaptopurine was stopped: 2 months-10 years) or at time of conception (n = 37), were studied (Francella et al., 2003) . These groups were compared with pregnancies fathered by men without mercaptopurine exposure (n = 73). There were no significant differences in conception failures among mercaptopurine exposed male patients compared with controls (one child with a birth defect in the exposed group and two children with birth defects in the unexposed group, relative risk (RR) 0.85, 95% CI 0.47, 1.55, P > 0.05). Relevant factors including age of mother, smoking status and use of medication by mother and type of IBD were included in the regression analyses.
Likewise, Teruel et al. did not observe significant differences regarding fertility impairment, unsuccessful pregnancies, premature births and congenital malformations between azathioprine/mercaptopurine exposed pregnancies (n = 46) and a control group of unexposed pregnancies fathered by men with IBD (n = 84) (unsuccessful pregnancies 10.9% vs. 13.1% (OR 0.79, 95% CI 0.22, 2.85), preterm births 4.3% vs. 2.4% (OR 1.3, 95% CI 0.22, 7.61), low birth weight 6.5% vs. 6% (OR 1.06, 95% CI 0.25, 4.54) and congenital malformations 2.2% vs. 2.4% (OR 0.82, 95% CI 0.08, 9), all P > 0.05) (Teruel et al., 2010) .
At last, in an often discussed case report, an adverse birth outcome was described of a newborn diagnosed with Wilms tumour, aniridia, genital anomalies and retardation, together known as the WAGR syndrome (Ben-Neriah and Ackerman, 2001 ). This newborn was fathered by a 31 year old man with IBD, and using azathioprine (dosages 1.5 mg/kg daily) during conception, and a healthy mother (30 years old). Additional information on disease activity, family history, alcohol and smoking status was not reported.
Rheumatic conditions and unspecified cohorts
Male fertility
In a case series about male fertility in men with SLE and immunosuppressive therapy, one patient with azathioprine (100 mg/day) and prednisone treatment (10 mg/day) was described (Silva et al., 2002) . This patient did not have abnormalities in testicular volume (both testis 20 ml) and hormone levels were normal (plasma LH 5.3 IU/I, plasma FSH 6.5 IU/I, testosterone 571 ng/ml and prolactin 31 ng/ml). However, in three semen samples an abnormal semen morphology (WHO normal morphology of 15%) was found. Reduced semen quality was also observed in three other SLE patients in this cohort treated with cyclophosphamide and prednisone.
Birth outcomes
In two nationwide Danish cohort studies, the risk of congenital abnormalities as a possible result of paternal azathioprine or mercaptopurine exposure was retrospectively studied (Norgard et al., 2004 (Norgard et al., , 2016 . In a paternally exposed group of 54 children, four children (7.4%) with congenital abnormalities were identified, compared with 2 234 children with congenital abnormalities in the control group (n = 57 195) (3.9%, adjusted OR 1.8, 95% CI 0.7, 5.0, P > 0.05) (Norgard et al., 2004) . The same researchers also evaluated the effects of paternal azathioprine or mercaptopurine exposure within 3 months of conception on adverse birth outcomes, and compared these with children without paternally thiopurine exposure during conception, in a larger population (699 exposed and 1 012 624 unexposed children) (Norgard et al., 2016) . Although not mentioned in the article, there is a possibility that this was a partially overlapping cohort of exposed children used in their previous study from 2004 (Norgard et al., 2004) . The researchers did not observe significantly increased risks of adverse birth outcomes in the exposed cohort of children (congenital abnormalities: adjusted OR 0.82, 95% CI, 0.53, 1.28, preterm birth: adjusted OR 0.17, 95% CI 0.72, 1.92 and small for gestational age: adjusted OR 1.38, 95% CI 0.76, 2.51, all P > 0.05). When the researchers restricted their analyses to fathers with IBD, 514 children fathered by men treated with azathioprine or mercaptopurine within 3 months of conception were identified. Also in this specific patient group, risks of adverse birth outcomes did not vary significantly between exposed and unexposed children (congenital abnormalities: adjusted OR 0.96, 95% CI 0.59, 1.58, preterm birth: adjusted OR 1.35, 95% CI 0.74, 2.46 and small for gestational age: adjusted OR 1.45, 95% CI 0.73, 2.91, all P > 0.05).
Hoeltzenbein et al. compared the risk of pregnancy complications and birth defects after paternally exposure to azathioprine or mercaptopurine (n = 115) to a control group of non-exposed pregnancies (n = 341) in a prospective study (Hoeltzenbein et al., 2012) . Mean dose of azathioprine was 150 mg per day. The rate of (major) birth defects was not increased in the exposed group (all birth defects: 11% in exposed vs. 7.7% in the control group and major birth defects: 3.0% in exposed vs. 2.2% in the control group, both P > 0.05). A slightly increased rate of spontaneous abortions was observed in the exposed group, but this was not significant (the cumulative incidence in the exposed group was 19% and 13% in controls). There were no malformations or chromosomal aberrations reported in the exposed miscarriages.
Summary of outcomes and meta-analysis of congenital anomalies
A total of 83 men with thiopurine therapy who underwent semen analyses were described in the literature (Silva et al., 2002; Dejaco et al., 2001; Handelsman et al., 1984; Lingardh et al., 1974; Phadke et al., 1970; Valer et al., 2017) . In 36 patients with thiopurine monotherapy, and 47 patients with prednisone co-therapy, no correlation between (long-term) therapy and testicular function (testicular volume, plasma LH, FSH, testosterone, estradiol and prolactin) or seminal quality (total sperm count, sperm density, sperm motility, sperm morphology, ejaculate volume, antisperm antibodies and zinc levels) was observed. There were no studies available, in which chromosomal damage in male germ cells or alterations in spermatogenesis in thiopurine exposed men, were examined.
Six case-control studies, included in this meta-analysis, reported on the incidence of congenital defects in paternally thiopurine exposed offspring (Rajapakse et al., 2000; Norgard et al., 2004 Norgard et al., , 2016 Hoeltzenbein et al., 2012; Francella et al., 2003; Teruel et al., 2010) . In total, 964 children fathered by azathioprine or mercaptopurine exposed men during conception were described (Table III) . Out of these exposed pregnancies, 51 children (5.3%) had birth defects possibly as a result of paternally thiopurine exposure. In the control groups consisting of unexposed pregnancies, 50 817 out of 1 070 487 children (4.7%) with birth defects were reported. An estimated OR for congenital anomalies was 1.32 with 95% CIs between 0.75 and 2.34. The heterogeneity between the studies was insignificant and could be interpreted as unimportant to moderate, according to the Cochrane handbook (I 2 -test = 42%, P > 0.05). With regards to the two studies conducted by Norgard et al., there was uncertainty about the possibility that their cohort from 2016 was partially overlapping their cohort from 2004.
Excluding their prior study from 2004, however, did not affect our meta-analysis for congenital malformations (OR 1.23, 95% CI 0.62, 2.43). As shown in Table III , the 95% CI range of the study of Rajapakse et al. was very wide reflecting the small sample size of the study. The individual CI's together with the final pooled result are depicted in the Forest plot in Fig. 4 , where 'log odds ratio' is shown to overcome scale issues (Morris and Gardner, 1988) .
This meta-analysis was limited by the number of included studies and the sample size of each study. A power analysis was used to determine the necessary sample size to reach a sufficient degree of confidence in the results. To address the question of safety of paternal thiopurine usage, a future study should aim to reach a sample size of at least 2000 men in the thiopurine exposed group, in proportion to the pooled sample size in this meta-analysis. The required number of men becomes higher if different studies are pooled together. Also, a randomized setting would require more men in the intervention group, together with fewer men in the control group. In the future when more studies will be published, a cumulative meta-analysis could be performed to show the influence of adding new studies on the pooled estimate and to identify patterns in the data.
Discussion
Thiopurines in animals
The present study provides a detailed review of the literature on the association between thiopurines and male fertility and reproduction safety derived from animal and human studies. In fourteen non-human studies, mostly performed in male mice exposed to high doses mercaptopurine (in doses of two to 20 times the HED), the mutagenicity of thiopurines in germ cells was demonstrated. Remarkably, mercaptopurine caused chromosomal damage and aberrations in the late pre-meiotic stages, indicating that mercaptopurine has a selective, stage-specific, effect on the spermatogenesis of these mammals. Thiopurines administered in low doses as used in the treatment of immune-mediated diseases such as IBD did not have mutagenic and teratogenic effects (Karl et al., 1991; Ligumsky et al., 2005; Bendre et al., 2007) . Ligumsky et al. demonstrated that mercaptopurine in low doses did not affect sperm quality or increase the risk of congenital malformations in mice, but pregnancy outcome was poorer, indicating occult sperm damage (Ligumsky et al., 2005) . Although findings in mammalian species can, to some extent, be generalized to other mammals, there are important differences making it difficult to interpret these findings and relate them to humans (Cooke and Saunders, 2002) . There are differences between humans and animals in drug absorption, drug metabolism, and the impact of the administered drug on local tissues and the male reproductive system. Another crucial difference might be the shorter turnover of the epithelial cells and a shorter total period of time for spermatogenesis (approximately 50 days) in mice and rats, compared to humans (approximately 90 days) (Karl et al., 1991) .
Thiopurines in humans
In humans, testicular function and the quality of semen were not adversely affected by thiopurine therapy as reported in six studies (Silva et al., 2002; Dejaco et al., 2001; Handelsman et al., 1984; Lingardh et al., 1974; Phadke et al., 1970; Valer et al., 2017) . In total, 83 men, including 47 men with prednisone co-therapy, were described in these studies. In none of the studies, was an association between thiopurine exposure and poor sperm quality or testicular function implied, and impaired fertility was often related to underlying disorders. In six case-control studies, a total of 964 children fathered by azathioprine or mercaptopurine exposed men during conception were described (Rajapakse et al., 2000; Norgard et al., 2004 Norgard et al., , 2016 Hoeltzenbein et al., 2012; Francella et al., 2003; Teruel et al., 2010) . Out of these exposed pregnancies, 51 children (5.3%) had birth defects possibly as a result of paternal thiopurine exposure (compared to 4.7% children with birth defects in the unexposed groups all together). Only in one study, was the incidence of birth-related complications significantly increased (2 out of 13 exposed children had congenital abnormalities), when fathers were treated with mercaptopurine during conception (Rajapakse et al., 2000) . The estimated OR for congenital anomalies in paternally thiopurine exposed offspring was 1.32 with 95% CIs between 0.75 and 2.34. It is important to note that the estimate was largely influenced by the limited availability of data. The incidence of congenital abnormalities in the general population has been estimated at 3% of all live births (Centers for Disease and Prevention, 2008) . In the included studies in this metaanalysis, the rate of congenital anomalies was relatively higher in both thiopurine exposed and unexposed groups (5.3% and 4.7%, respectively) (Table III) . In the majority of these studies, comparison groups were male patients with chronic diseases (with mild disease activity or in remission) without thiopurine therapy. It is possible that the slightly increased risk of birth defects could be a consequence of paternal chronic disease rather than thiopurine exposure, when compared with the general (disease-free) population. In both male and female patients, chronic illnesses have an impact on all aspects of life, including the quality of reproductive and sexual health, due to psychological and physical symptoms (Ostensen, 2017) . In multiple reports on men with SLE without thiopurine exposure, poor gonadal and sexual function as a result of disease activity and hormone disturbances, has been described (Soares et al., 2007; Suehiro et al., 2008) . Likewise, in men with IBD, several pathophysiological features have been related to a reduced fertility and poor pregnancy outcomes (Shin and Okada, 2016; Farthing and Dawson, 1983) . In women with IBD, adverse pregnancy outcomes have been associated with flares throughout the pregnancy, but not with thiopurine exposure (Akbari et al., 2013; van der Woude et al., 2015; Jharap et al., 2014) .
Limitations
The available data regarding the safety of paternal thiopurine exposure, and the influence of thiopurines on semen quality and testicular function, are very limited (n = 964 and n = 83, respectively). Future studies with larger sample sizes (including at least 2000 thiopurine treated men as computed with a power analysis) are needed to sufficiently address the question about the safety of thiopurines in men's fertility and offspring. Further, novel methodologies, including a cumulative meta-analysis, might be considered to perform a more precise analysis as more studies become available.
Additionally, current data are derived from case series and observational studies with small patient groups. Almost all studies (with exception of three trials (Francella et al., 2003; Teruel et al., 2010; Valer et al., 2017) ) were rated low or very low, in accordance with the GRADE criteria's to assess the quality of evidence (Balshem et al., 2011) . Larger studies performed by Norgard et al. were retrospective questionnaire designed studies, which are vulnerable to selection-bias and confounding (Norgard et al., 2004 (Norgard et al., , 2016 . Similarly, Rajapakse et al., who demonstrated a significant negative effect of thiopurine exposure on the birth outcome, conducted a small-sized study with a retrospective questionnaire design and without exclusion of potential confounders by performing a statistical regression (Rajapakse et al., 2000) . Potential confounders linked to congenital abnormalities (e.g. disease activity, maternal health and age, nutritional status, alcohol abuse, smoking status, socioeconomic and environmental factors) may have contributed to the findings in the studies (Egbe, 2015) .
Another important limitation was the possibility of heterogeneity among the studies, due to heterogeneous populations, different study designs and sample sizes, for which reason the random effects model was used. In three out of six case-control trials included in this metaanalysis, underlying disorders and disease activity in patient groups, and health characteristics in comparison groups, were not always accurately reported (Norgard et al., 2004 (Norgard et al., , 2016 Hoeltzenbein et al., 2012) . As mentioned earlier, disease activity has been linked to poor reproduction capacity and pregnancy outcomes in female and male patients. Furthermore, reporting bias including language bias, citation bias and publication bias, could possibly have contributed to our findings (Thornton and Lee, 2000) . The presence of reporting bias could not be statistically assessed due to the low number of included studies in the meta-analysis. Therefore, our findings should be interpreted carefully concerning the lack of good evidence in the included, poorquality, studies and the limitations of our meta-analysis.
Finally, no studies on thioguanine therapy and male fertility and/or reproduction were identified. Thioguanine is especially used in the treatment of haematological malignancies, but is also increasingly being applied as an escape therapy in patients with IBD and autoimmune hepatitis who have to discontinue azathioprine or mercaptopurine therapy due to intolerance or resistance. Larger, prospective studies that adjust for confounding factors and have appropriate comparison groups are needed to evaluate the effects of azathioprine, mercaptopurine and also thioguanine on men's fertility and their offspring to provide potential fathers with adequate information.
Implications for clinical practice
Thiopurines are classified as category D; drugs that may have potential risk to the foetus, but the benefits from its use in pregnancy are considered acceptable. Maternal thiopurine use does not seem to be associated with reduced fertility or adverse birth events as described in multiple reviews and meta-analyses (Kanis et al., 2017; Akbari et al., 2013; Francella et al., 2003; Hutson et al., 2013) . Interestingly, in a casecontrol trial on the safety of thiopurines in female patients with IBD, thiopurine treated patients had better pregnancy outcomes than those without thiopurine therapy, emphasizing the importance of disease control throughout pregnancy (Casanova et al., 2013) . According to the European Crohn's and Colitis Organization (ECCO) guidelines, thiopurine use during conception and pregnancy is accepted in the management of IBD (van der Woude et al., 2015) . For men, comparable guidelines on fertility, conception and paternal drug recommendations should be established as well. Thiopurine treated potential fathers should be appropriately counselled about the unclear evidence regarding the effects of thiopurines on their fertility and offspring, and the association of undertreated illnesses with poor pregnancy outcomes, which may outweigh possible risks of thiopurine treatment.
Conclusion
There is limited data and a lack of solid evidence regarding the possible effects of thiopurines on testicular function, semen quality and paternally exposed offspring. In animal studies, azathioprine and mercaptopurine adversely affected germ cells and reproduction at levels exceeding normal therapeutic concentrations. In humans, data from underpowered, observational studies indicate that thiopurines do not evidently impair the quality of semen and testicular function, or harm paternally exposed offspring. However, these data are inconclusive and larger, epidemiological studies evaluating the safety of thiopurines in men and their offspring are mandatory in order to adequately counsel thiopurine treated patients who wish to conceive.
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